Sarepta Therapeutics, Inc. (SRPT) stock
SRPTNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 5, 2026Score 11/3085% below fair value
$16.07+0.06 (+0.37%)
Close on Nov 13, 2026Market cap $1.70BP/E –Yield –
Sarepta Therapeutics total debt
Total debt is short-term plus long-term borrowings on the balance sheet at the end of each period.
Sarepta Therapeutics's total debt was $157.97M at Sep 30, 2026. For fiscal 2025 it was $0. The highest annual figure on record is $105.48M in fiscal 2023.
Annual total debt
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $0 | – |
| FY2024 | Dec 31, 2024 | $0 | -100.0% |
| FY2023 | Dec 31, 2023 | $105.48M | – |
| FY2022 | Dec 31, 2022 | $0 | -100.0% |
| FY2014 | Dec 31, 2014 | $2.36M | +41.5% |
| FY2013 | Dec 31, 2013 | $1.67M | -5.1% |
| FY2012 | Dec 31, 2012 | $1.76M | -4.6% |
| FY2011 | Dec 31, 2011 | $1.84M | -4.2% |
| FY2010 | Dec 31, 2010 | $1.92M | – |
Quarterly total debt
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $157.97M | +72.6% |
| Q4 FY2025 | Dec 31, 2025 | $0 | -100.0% |
| Q4 FY2024 | Dec 31, 2024 | $0 | -100.0% |
| Q3 FY2024 | Sep 30, 2024 | $91.60M | – |
| Q2 FY2024 | Jun 30, 2024 | $91.51M | – |
| Q1 FY2024 | Mar 31, 2024 | $105.59M | – |
| Q4 FY2023 | Dec 31, 2023 | $105.48M | – |
| Q4 FY2022 | Dec 31, 2022 | $0 | – |
See a number that looks wrong?